SILVER SPRING, Md., March 11, 2026
The U.S. Food and Drug Administration (FDA) has launched a new unified safety monitoring platform called the FDA Adverse Event Monitoring System (AEMS), marking a major step forward in the agency’s efforts to modernize post-market surveillance of regulated products. The platform provides a centralized system for analyzing and accessing adverse event reports related to drugs, biologics, vaccines, cosmetics, medical devices, and animal products, significantly improving transparency and accessibility of safety data. According to the FDA, the new system replaces several outdated and fragmented databases with a single streamlined dashboard that allows scientists, regulators, healthcare professionals, and the public to analyze safety reports more efficiently. The launch represents one of the largest digital transformations in the agency’s history and aims to strengthen the FDA’s ability to detect potential safety signals, evaluate product risks, and protect public health through improved data infrastructure and real-time monitoring capabilities.
Unified Platform Modernizes Safety Reporting
The AEMS platform consolidates multiple legacy reporting systems into a unified digital environment, addressing longstanding challenges in the FDA’s adverse event reporting infrastructure. Previously, safety reports were distributed across seven separate databases, including systems used for pharmaceuticals, vaccines, medical devices, animal drugs, food products, and tobacco-related products.
These disconnected systems processed approximately six million adverse event reports annually, making it difficult for analysts to quickly identify patterns or emerging safety concerns. With the launch of AEMS, all adverse event reports submitted to the agency will now be aggregated into a single searchable platform, allowing users to analyze safety data more effectively. The system also provides a streamlined dashboard interface and improved search functionality, enabling faster access to safety reports for regulatory scientists and external researchers alike.
The FDA noted that future updates will further expand the platform’s capabilities by integrating advanced analytics tools and application programming interfaces (APIs) designed to support data sharing and research.
Advertisement
Real-Time Data Improves Transparency and Surveillance
A key feature of the new platform is the ability to publish adverse event reports in real time, significantly improving transparency in the FDA’s pharmacovigilance and product safety monitoring processes. Previously, many adverse event reports were released only on a quarterly basis, limiting the speed at which researchers and regulators could access new information. The AEMS system will now allow safety reports submitted by patients, healthcare professionals, product manufacturers, and consumers to be made available more quickly while maintaining strict safeguards to protect personally identifiable information.
By providing real-time access to adverse event data, the FDA expects the system to support earlier detection of potential safety signals and enable faster regulatory responses to emerging risks. Improved accessibility to safety data may also reduce the number of Freedom of Information Act (FOIA) requests submitted to the agency, since the information will already be available through the public platform.
Replacing Legacy Systems and Reducing Costs
The launch of AEMS will gradually replace several long-standing adverse event reporting systems used across the FDA. These legacy platforms include FAERS for drug and biologic reports, VAERS for vaccine safety monitoring, and AERS databases for animal drug and animal food reports, along with additional systems that track medical device incidents, food complaints, and tobacco product safety events. By migrating these systems into a single digital infrastructure, the FDA aims to improve operational efficiency while reducing maintenance costs associated with maintaining multiple outdated platforms. According to the agency, the legacy systems collectively cost approximately $37 million annually to operate, while the new consolidated system is expected to save approximately $120 million over the next five years. The modernization effort is also expected to improve the agency’s ability to monitor safety signals across different product categories, ensuring that emerging health risks can be identified and addressed more rapidly.
Strengthening Post-Market Safety Oversight
The FDA emphasized that adverse event reporting remains a critical component of post-market surveillance, allowing regulators to monitor product safety after medicines and medical technologies have entered the market. While adverse event reports alone do not establish causality, they often serve as early indicators of potential safety risks, helping regulators identify patterns that may warrant further investigation.
The AEMS platform is designed to strengthen these capabilities by providing more comprehensive access to safety data and improved analytical tools for regulatory scientists and researchers. As the healthcare industry continues to develop increasingly complex therapies, including biologics, advanced medicines, and novel medical technologies, robust pharmacovigilance infrastructure will remain essential to protecting patient safety. With the launch of AEMS, the FDA aims to create a modern, transparent, and data-driven safety monitoring system that supports both regulatory decision-making and public health protection.
Source: U.S. Food and Drug Administration (FDA) press release
